Page last updated: 2024-08-26

7-amino-4-methylcoumarin and Kahler Disease

7-amino-4-methylcoumarin has been researched along with Kahler Disease in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Bernatowicz, M; Bolkun, L; Galar, M; Kalita, J; Kloczko, J; Ostrowska, H; Romaniuk, W	1

Other Studies

1 other study(ies) available for 7-amino-4-methylcoumarin and Kahler Disease

Article	Year
High chymotrypsin-like activity in the plasma of patients with newly diagnosed multiple myeloma treated with bortezomib is predictive of a better response and longer PFS. Annals of hematology, 2018, Volume: 97, Issue:10 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bortezomib; Combined Modality Therapy; Coumarins; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Molecular Targeted Therapy; Multiple Myeloma; Neoplasm Proteins; Proportional Hazards Models; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Serine Endopeptidases; Treatment Outcome	2018

Article

Year

High chymotrypsin-like activity in the plasma of patients with newly diagnosed multiple myeloma treated with bortezomib is predictive of a better response and longer PFS.

Annals of hematology, 2018, Volume: 97, Issue:10

Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bortezomib; Combined Modality Therapy; Coumarins; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Molecular Targeted Therapy; Multiple Myeloma; Neoplasm Proteins; Proportional Hazards Models; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Serine Endopeptidases; Treatment Outcome

2018